The Justice Department last week had accused Regeneron of manipulating Medicare's drug-pricing process by inflating the average sales price for its Eylea drug.
(Reporting by Kanjyik Ghosh in Bengaluru; Editing by Shilpi Majumdar)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
892.5 USD | +1.05% | -0.85% | +1.62% |
Apr. 26 | Regeneron Faces Q1 Seasonality Despite Eylea HD Launch, Oppenheimer Says | MT |
Apr. 26 | Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,125 | MT |
(Reuters) - Regeneron Pharmaceuticals said on Monday the U.S. Justice Department's complaint against the company misreporting the average sales price for its macular degeneration drug Eylea is "meritless" and it plans to defend this case in court.
The Justice Department last week had accused Regeneron of manipulating Medicare's drug-pricing process by inflating the average sales price for its Eylea drug.
(Reporting by Kanjyik Ghosh in Bengaluru; Editing by Shilpi Majumdar)
1st Jan change | Capi. | |
---|---|---|
+1.62% | 95.28B | |
-2.63% | 103B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B | |
-24.98% | 8.24B |